Original Article

Kidney International (2007) 72, 1367–1373; doi:10.1038/sj.ki.5002516; published online 5 September 2007

Rosiglitazone decreases albuminuria in type 2 diabetic patients

Y Miyazaki1, E Cersosimo1, C Triplitt1 and R A DeFronzo1

1Texas Diabetes Institute, University of Texas Health Science Center, San Antonio, Texas, USA

Correspondence: RA DeFronzo, Diabetes Division, University of Texas Health Science Center, Room no. 3.380S, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900, USA. E-mail: albarado@uthscsa.edu

Received 27 February 2007; Revised 7 June 2007; Accepted 3 July 2007; Published online 5 September 2007.

Top

Abstract

Thiazolidinediones are insulin-sensitizing compounds that reduce plasma glucose and improve the lipid profile of type 2 diabetic patients. We determined the effect of rosiglitazone in 15 type 2 diabetic patients and compared these results to 14 randomly assigned placebo patients. After 3 months, the urinary albumin to creatinine ratio was significantly decreased, while the glucose metabolic clearance rate, during insulin clamp, was significantly increased by rosiglitazone compared to the placebo group. Fasting free fatty acid and tumor necrosis factor-alpha (TNF-alpha) levels were significantly decreased, while the adiponectin concentration was significantly increased by rosiglitazone treatment. The percentage decrease in albuminuria correlated with the decrease in fasting plasma glucose, free fatty acids TNF-alpha and the increase in fat mass, plasma adiponectin, and glucose metabolic clearance rate. Stepwise linear regression analysis showed the decrease in TNF-alpha and the increase in adiponectin were independently associated with decreased albuminuria. Our study indicates that thiazolidinediones may be useful to prevent nephropathy in type 2 diabetic patients.

Keywords:

albuminuria, type 2 diabetes, thiazolidinediones, adipocytokines, insulin resistance

Top

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated

REVIEWS

Mechanisms of Disease: hepatic steatosis in type 2 diabetes?pathogenesis and clinical relevance

Nature Clinical Practice Endocrinology & Metabolism Review (01 Jun 2006)

Mechanisms of Disease: hepatic steatosis in type 2 diabetes?pathogenesis and clinical relevance

Nature Clinical Practice Endocrinology & Metabolism Review (01 Jun 2006)

Mechanisms of Disease: adipocytokines and visceral adipose tissue?emerging role in nonalcoholic fatty liver disease

Nature Clinical Practice Gastroenterology & Hepatology Review (01 Jun 2005)

Mechanisms of Disease: adipocytokines and visceral adipose tissue?emerging role in nonalcoholic fatty liver disease

Nature Clinical Practice Gastroenterology & Hepatology Review (01 Jun 2005)

See all 21 matches for Reviews

Extra navigation

.
ADVERTISEMENT